Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SU093
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
SU093 is a natural product-derived small molecule inhibitor of guanylate binding protein 1 (GBP1), currently under investigation for the treatment of advanced and taxane-resistant ovarian cancer. Developed at Stanford University, SU093 functions by stabilizing GBP1 in a nonbinding conformation, which prevents its interaction with the pro-survival kinase PIM1 and blocks its nuclear translocation. This mechanism disrupts tubulin dynamics and induces G1 phase arrest and apoptosis in cancer cells. By targeting the GBP1-mediated resistance pathway, SU093 aims to restore sensitivity to chemotherapeutic agents like paclitaxel and carboplatin.
02
Targets
GBP1 (Guanylate-binding protein 1)
Beyond the preview
Go deeper on SU093.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SU093.